

PROTON THERAPY CENTER BEGINS PATIENT TREATMENTS IN PRAGUE

IBA continues to deliver on time fully equipped proton therapy centers around the globe

Prague, December 11, 2012 — IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, announces that cancer patients are now being treated with IBA's proton beam technology at the new Proton Therapy Center Czech in Prague.

Offering four state-of-the-art patient treatment rooms and the latest proton beam technology developed by Belgium-based IBA, Proton Therapy Center Czech will attract adult and pediatric cancer patients from throughout Europe, Asia and Africa who are seeking advanced cancer care with lower treatment-related side effects.

The four-story facility is the fifth proton center to open in Europe and is one of the most advanced cancer centers in the world. When fully operational, Proton Therapy Center Czech is expected to treat about 2,500 cancer patients a year.

With the first patient treatments beginning in Prague this week, IBA continues to deliver on time to equip proton therapy centers and prepare them to treat patients. Such assurance helps medical institutions reduce their technological and financial risk.

"There is urgency to open more proton centers around the world," said Olivier Legrain, Chief Executive Officer at IBA. *"More than 78,000 people a year are diagnosed with cancer in the Czech Republic alone. An IBA installation in Prague advances our mission to protect, enhance and save lives by expanding access to proton beam treatments for cancer patients in the Czech Republic and around the world."*

The IBA-installed proton beam system includes a cyclotron, beam line, three gantry treatment rooms and one fixed-beam treatment room. Each treatment room at Proton Therapy Center Czech is equipped with the latest advancements in IBA's Pencil Beam Scanning dedicated nozzle technology. With a beam spot as fine as 3 millimeters, Pencil Beam Scanning permits high-definition conformity to the tumor and rapid dose delivery.

"Pencil Beam Scanning offers incredible advantages for cancer care," said Professor Dr. Manfred Herbst, the Medical Director of Proton Therapy Center Czech. *"It is the most advanced way to treat tumors located adjacent to vital organs, helping to ensure optimal cancer therapy and minimal side effects."*

The former managing director of the Rinecker Proton Center in Munich, Germany, Professor Dr. Herbst said that the goal of Proton Therapy Center Czech is *"to maximize cancer curability in the shortest time possible by hypo fractionation and applying the maximal proton dose."*

"Eventually, the aim is to decrease the cost of treatment and to increase the number of patients treated with protons," Professor Dr. Herbst said. *"We will use protons to treat pediatric cancers, head and neck cancers, eye and brain cancers, lung cancer, prostate cancer and pancreatic and liver cancer and especially gynecological tumors in the pelvis."*

Press release



While the Proton Therapy Center Czech was privately funded, it was developed in partnership with the first Faculty of Medicine at Charles University and the Faculty of Nuclear Sciences and Physical Engineering at the Czech Technical University. Both educational facilities are located in Prague.

The privately managed center operates within the Czech Republic's network of public clinical centers. The facility also serves international patients and is staffed by multilingual medical personnel to enhance patient-centered cancer care.

Proton therapy is increasingly considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a three dimensional controlled range, directly within the tumor and sparing healthy surrounding tissue.

ABOUT PROTON THERAPY CENTER CZECH

Proton Therapy Center Czech is a privately owned and operated cancer center that relies on the power of proton beams to cure cancers with minimal treatment-related side effects. Privately funded and managed, the center operates in cooperation with the public hospitals and clinics of the Czech Republic. The center also serves cancer patients from Europe, the Russian Federation and other countries.

Website: <http://en.ptc.cz/>

ABOUT IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The company's expertise lies in the development of next-generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA's leading fully integrated IntegraLab[®] radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the U.S., and is expanding into emerging markets. The company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT.

Website: www.iba-protontherapy.com

Contact

IBA

William Hansen

Director of Global Marketing

p. 00-1-612-804-5559

e. William.Hansen@iba-group.com

Proton Therapy Center Czech

Jana Kulhankova, Ph.D.

Marketing Manager

p. +420 222 998 921

e. jana.kulhankova@ptc.cz